A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure

European Journal of Internal Medicine

Volumn 44, Issue , 2017, Pages 31-38

  Lichtenauer, Michael ^a   Jirak, Peter ^a   Wernly, Bernhard ^a   Paar, Vera ^a   Rohm, Ilonka ^b   Jung, Christian ^c   Schernthaner, Christiana ^a   Kraus, Johannes ^a   Motloch, Lukas J ^a   Yilmaz, Atilla ^d   Hoppe, Uta C ^a   Christian Schulze, P ^b   Kretzschmar, Daniel ^b   Pistulli, Rudin ^b  

^a UNIVERSITY OF SALZBURG   (Austria)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d Clinic of Internal Medicine II   (Germany)

Author keywords

Biomarkers; Chronic heart failure; GDF 15; H FABP; sST2; suPAR

Indexed keywords

FATTY ACID BINDING PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; SOMATOSTATIN RECEPTOR 2; UROKINASE RECEPTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; FATTY ACID BINDING PROTEIN 3; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ADULT; ARTICLE; CARDIOMYOPATHY; COMPARATIVE STUDY; CONTROLLED STUDY; DILATIVE CARDIOMYOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; AGED; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; COMPLICATION; FEMALE; GERMANY; HEART LEFT VENTRICLE FUNCTION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

AGED; BIOMARKERS; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; CHRONIC DISEASE; FATTY ACID BINDING PROTEIN 3; FEMALE; GERMANY; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85020124432     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2017.05.027     Document Type: Article

References (35)

1. Andersson, C., Enserro, D., Sullivan, L., Wang, T.J., Januzzi, J.L. Jr., Benjamin, E.J., et al. Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: the Framingham heart study. Atherosclerosis 248 (2016), 245–251.
2. Ben-Gal, Y., Mohr, R., Feit, F., Ohman, E.M., Kirtane, A., Xu, K., et al. Surgical versus percutaneous coronary revascularization for multivessel disease in diabetic patients with non-ST-segment-elevation acute coronary syndrome: analysis from the acute catheterization and early intervention triage strategy trial. 2015, Circulation, Cardiovascular Interventions.
3. Bleumink, G.S., Knetsch, A.M., Sturkenboom, M.C., Straus, S.M., Hofman, A., Deckers, J.W., et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure the Rotterdam study. Eur Heart J 25 (2004), 1614–1619.
4. Briasoulis, A., Androulakis, E., Christophides, T., Tousoulis, D., The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail Rev 21 (2016), 169–176.
5. Carson, P., Wertheimer, J., Miller, A., O'Connor, C.M., Pina, I.L., Selzman, C., et al. The STICH trial (surgical treatment for ischemic heart failure): mode-of-death results. JACC Heart Fail 1 (2013), 400–408.
6. Ciccone, M.M., Cortese, F., Gesualdo, M., Riccardi, R., Di Nunzio, D., Moncelli, M., et al. A novel cardiac bio-marker: ST2: a review. Molecules 18 (2013), 15314–15328.
7. Cook, C., Cole, G., Asaria, P., Jabbour, R., Francis, D.P., The annual global economic burden of heart failure. Int J Cardiol 171 (2014), 368–376.
8. Damman, P., Kempf, T., Windhausen, F., van Straalen, J.P., Guba-Quint, A., Fischer, J., et al. Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: an invasive versus conservative treatment in unstable coronary syndromes (ICTUS) substudy. Int J Cardiol 172 (2014), 356–363.
9. Eugen-Olsen, J., Andersen, O., Linneberg, A., Ladelund, S., Hansen, T.W., Langkilde, A., et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268 (2010), 296–308.
10. Hacker, S., Lambers, C., Pollreisz, A., Hoetzenecker, K., Lichtenauer, M., Mangold, A., et al. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. J Clin Lab Anal 23 (2009), 372–379.
11. Hanley, J.A., McNeil, B.J., The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982), 29–36.
12. Hausenloy, D.J., Botker, H.E., Engstrom, T., Erlinge, D., Heusch, G., Ibanez, B., et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J, 2016.
13. Japp, A.G., Gulati, A., Cook, S.A., Cowie, M.R., Prasad, S.K., The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol 67 (2016), 2996–3010.
14. Kabekkodu, S.P., Mananje, S.R., Saya, R.P., A study on the role of heart type fatty acid binding protein in the diagnosis of acute myocardial infarction. J Clin Diagn Res 10 (2016), OC07–OC10.
15. Kakkar, R., Lee, R.T., The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7 (2008), 827–840.
16. Kempf, T., Sinning, J.M., Quint, A., Bickel, C., Sinning, C., Wild, P.S., et al. Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. Circ Cardiovasc Genet 2 (2009), 286–292.
17. Kempf, T., Wollert, K.C., Growth-differentiation factor-15 in heart failure. Heart Fail Clin 5 (2009), 537–547.
18. Mildner, M., Storka, A., Lichtenauer, M., Mlitz, V., Ghannadan, M., Hoetzenecker, K., et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 87 (2010), 769–777.
19. Miller, A.M., Liew, F.Y., The IL-33/ST2 pathway–a new therapeutic target in cardiovascular disease. Pharmacol Ther 131 (2011), 179–186.
20. Mosterd, A., Hoes, A.W., Clinical epidemiology of heart failure. Heart 93 (2007), 1137–1146.
21. Niizeki, T., Takeishi, Y., Arimoto, T., Takabatake, N., Nozaki, N., Hirono, O., et al. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail 13 (2007), 120–127.
22. Pistulli, R., Konig, S., Drobnik, S., Kretzschmar, D., Rohm, I., Lichtenauer, M., et al. Decrease in dendritic cells in endomyocardial biopsies of human dilated cardiomyopathy. Eur J Heart Fail 15 (2013), 974–985.
23. Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
24. Pouleur, A.C., Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction?. Clin Chim Acta 443 (2015), 9–16.
25. Reiter, M., Twerenbold, R., Reichlin, T., Mueller, M., Hoeller, R., Moehring, B., et al. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction. Heart 99 (2013), 708–714.
26. Ruan, L.B., He, L., Zhao, S., Zhu, P., Li, W.Y., Prognostic value of plasma heart-type fatty acid-binding protein in patients with acute pulmonary embolism: a meta-analysis. Chest 146 (2014), 1462–1467.
27. Schmieder, A., Multhoff, G., Radons, J., Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine 60 (2012), 514–521.
28. Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (2005), 479–490.
29. Sehestedt, T., Lyngbaek, S., Eugen-Olsen, J., Jeppesen, J., Andersen, O., Hansen, T.W., et al. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 216 (2011), 237–243.
30. Thuno, M., Macho, B., Eugen-Olsen, J., suPAR: the molecular crystal ball. Dis Markers 27 (2009), 157–172.
31. van Riet, E.E., Hoes, A.W., Wagenaar, K.P., Limburg, A., Landman, M.A., Rutten, F.H., Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 18 (2016), 242–252.
32. Wach, S., Al-Janabi, O., Weigelt, K., Fischer, K., Greither, T., Marcou, M., et al. The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer. Int J Cancer 137 (2015), 1406–1416.
33. Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E. Jr., Colvin, M.M., et al. ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Circulation 2017. 2017.
34. Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E. Jr., Drazner, M.H., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
35. Zeyda, M., Wernly, B., Demyanets, S., Kaun, C., Hammerle, M., Hantusch, B., et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes (Lond) 37 (2013), 658–665.